Read More Pharma Industry News Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline. bySrinathNovember 13, 2025